[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557567":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":29,"responsibleParty":49,"collaborators":24,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":24,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":24,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":32,"whyStopped":24,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"AlRyada University for Science & Technology","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group (A)","EXPERIMENTAL","Patients will receive exercises, and sham Non-Invasive Neuromodulation, 3 sessions per week (one hour for each session) for 4 weeks.",[13,14],"Other: Aerobic Exercises","Other: Transcutaneous electrical nerve stimulation",{"label":16,"type":10,"description":17,"interventionNames":18},"Control group (B)","Patients will receive exercises as in group (A) in addition to Non-Invasive Neuromodulation 3 sessions per week (one hour for each session) for 4 weeks.",[13],[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Aerobic Exercises","Treadmill 20 minutes including 5 minutes warm up and 5 minutes cool.",[16,9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Transcutaneous electrical nerve stimulation","will be applied for all patients, which uses an asymmetrical biphasic alternating current in the continuous mode (pulse duration 100 µs, low frequency). TENS intensity will increase slowly, and patients will be instructed to indicate sensory threshold (ST); then, the intensity are going to increase until the sensation perceived as \"strong but comfortable\" (SC1). The duration will be for 30 minutes, 3times\u002F week for 4 weeks",[9],[30],{"facility":31,"status":32,"city":33,"state":34,"zip":24,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Al Ryada University for Science and Technology","RECRUITING","Sadat","Menoufia","Egypt","EG",{"type":38,"coordinates":39},"Point",[40,41],34.20837,31.22371,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":47,"phoneExt":24,"email":48},"Ahmed Alshimy, PHD","CONTACT","0201115116030","ahmed.alshimy@rst.edu.eg",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Ahmed Alshimy","Lecturer and Consultant in Physical Therapy at Department of Neurology and it's Surgery. Faculty of Physical Therapy Al Ryada University for Science and Technology, Egypt","100557567","effect-of-neuromodulation-on-pain-biomarkers-and-functional-outcome-in-patients-with-fibromyalgia-syndrome-100557567",false,"NCT06539793","Effect of Neuromodulation on Pain Biomarkers and Functional Outcome in Patients With Fibromyalgia Syndrome","Inclusion Criteria:\n\n1. Patients fibromyalgia from both genders.\n2. The duration of fibromyalgia is more than 6 month (all patients with history of cervical or lumbar pain) and following diagnosis of FM using the 2016 revised FM criteria, on the basis of the ACR-2010 criteria.\n3. Their ages will be ranged from 25-35 years old.\n4. They will be medically stable and have sufficient cognitive abilities that enable them to understand and follow instruction according to Montreal Cognitive Assessment (MoCA) \\>26.\n\nExclusion Criteria:\n\n1. Other Neurological diseases as stroke , multiple sclerosis, Parkinson's disease and motor neuron disease\n2. Pacemaker\n3. Spinal fusion-cervical or lumbar\n4. Metal implants in the spine\n5. Pregnancy\n6. Epilepsy\n7. Severe psychiatric disorder or alcohol and drug abuse.\n8. Unstable medical condition which could compromise the participant's welfare or confound the study results.\n9. Uncontrolled blood pressure or diabetes\n10. Visual or auditory problems.\n11. Active inflammatory conditions","ALL","25 Years","35 Years",{"count":63,"type":64},40,"ESTIMATED","INTERVENTIONAL",[67],"NA","Fibromyalgia is the third most common musculoskeletal condition in terms of prevalence, after lumbar pain and osteoarthritis. Its prevalence is around 2-4 % and is more frequent in women than in men; the prevalence is highest in age the range of 40-60 years.",[70],"Fibromyalgia Syndrome",[72,73,74,75,76],"Fibromyalgia","NEUROMODULATION","Centralization","PAIN BIOMARKERS","FUNCTIONAL OUTCOME","2024-08-05",{"date":79,"type":80},"2024-08-06","ACTUAL",{"date":82,"type":64},"2024-09-01",{"date":84,"type":64},"2025-07-03",{"name":51,"class":6},1]